MedPath

Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer

Phase 3
Completed
Conditions
Gastric Cancer
Interventions
Device: Ultrasonically activated Shears
Device: Conventional Monopolar Electrocautery
Registration Number
NCT01971775
Lead Sponsor
Seoul National University Hospital
Brief Summary

Surgery is the first standard treatment for stomach cancer, but it still has negative factors such as bleeding, leakage, closure, surgery part infection and cardiovascular and lung complication by general anesthesia.

electric cautery is used extensively in surgery room due to the utility of simultaneous severance and hemostasis. In some case, the electric current from vitality electrode may unexpectedly stimulate or damage nearby muscles and nerves. Ultrasonically activated shears (UAS) is a device to transform the protein of organ for organ incision or hemostasis. General advantages possibly include shortened operating time, decrease of operative blood loss, and relatively less damages to the normal organ. UAS is commonly used in the operation room, which is now considered as a secure and useful medical device for for tissue dissection and coagulation. Also, it is expected to lower the risk of surgery by reducing operating time and blood loss.

However, clinical evidence is not sufficient for this device until now. Therefore, in this study,

1. Evaluate the utility, efficacy, and safety of energy based device, in the case of open gastrectomy

2. Would like to compare the following two kinds of energy based devices. A. For conventional monopolar electrosurgery group : dissection and sealing will be conducted by conventional monopolar electrocautery device B. For UAS group : dissection and sealing will be conducted by UAS

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
56
Inclusion Criteria
  • Pathologically proven primary gastric adenocarcinoma
  • Patients who may undergo distal gastrectomy
  • Patients who qualified for open gastrectomy for gastric cancer stage T1-3, M0 according to the 7th International Union Against Cancer classification
  • 20 ≤ age ≤ 75
  • Patients with informed consent
Read More
Exclusion Criteria
  1. Previous abdominal operation Hx.
  2. Patients who are impossible to undergo Billroth-I reconstruction because of duodenal invasion caused by duodenal ulcers or gastric cancer
  3. Patients who have CT defined ascites prior to operation
  4. Patients with liver dysfunction defined as T.Bil>1.2 or albumin<3.0
  5. Patients with heart disease such as uncontrolled hypertension, history of angina or coronary artery disease, history of cardiomyopathy, Ventricular Ejection Fraction <50% measured by echocardiography
  6. Patients with renal dysfunction defined as creatinine>1.4 mg/dL or Blood Urea Nitrogen>26mg/dL
  7. Patients with severe pulmonary dysfunction defined as Forced Expiratory Volume at 1 second<1.0 L in Pulmonary Function Test
  8. Patients with abnormal coagulation (PT International Normalized Ratio >1.2 or activated Partial Thromboplastin Time>45 sec)
  9. Patients with uncontrolled diabetes
  10. Treatment with aspirin or antithrombotic agents within 7days before operation
  11. Treatment with anticoagulant drug
  12. History of preoperative stress dose steroid treatment
  13. Patients who the investigators believe will be ineligible for participation in the clinical trial
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Ultrasonically Activated ShearUltrasonically activated ShearsDissection and lymphovascular sealing with Ultrasonically Activated Shears
Conventional Monopolar ElectrocauteryConventional Monopolar ElectrocauteryDissection and lymphovascular sealing with Conventional Monopolar Electrocautery
Primary Outcome Measures
NameTimeMethod
Intraoperative blood losswithin a month
Amount of drain at postoperative periodwithin a month
Secondary Outcome Measures
NameTimeMethod
Postoperative hospital staywithin 2 months
Operation timewithin 2 months
Transfusionwithin 2 months
Inflammatory factors (Serum C-Reactive Protein and cytokines, ascites cytokines)within 2 months
4. Postoperative hospital stay Complicationswithin 2 months

Trial Locations

Locations (1)

Seoul National University Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath